Improvement of liver function and non-invasive fibrosis markers in hepatitis B virus-associated cirrhosis: 2years of entecavir treatment

Seung Kak Shin, Jeong Han Kim, Hyeonsu Park, Oh Sang Kwon, Hyun Jung Lee, Jong Eun Yeon, Kwan Soo Byun, Sang Jun Suh, Hyung Joon Yim, Yun Soo Kim, Ju Hyun Kim

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background and Aim: Entecavir (ETV) induces biochemical and histologic improvement of the liver in patients with chronic hepatitis B. This study aimed to confirm that 2years of ETV treatment improves liver function and non-invasive fibrosis markers in patients with hepatitis B virus (HBV)-associated cirrhosis. Methods: A total 472 naïve patients with HBV-associated cirrhosis was treated with ETV for at least 2years, between March 2007 and December 2012. Model for end-stage liver disease and Child-Pugh (CP) score were used to evaluate the improvement of liver function. Aspartate transaminase to platelet ratio index, FIB-4 index, and fibrosis index were used to evaluate the improvement of fibrosis. Results: The final 370 of 472 patients with HBV-associated cirrhosis were enrolled. Mean age was 51±10years, and 240 patients (64.9%) were men. The distribution of CP class was 71.1% in A, 24.6% in B, and 4.3% in C. Mean end-stage liver disease and CP score changed over the study period from 8.5±4.6 to 6.2±4.2 (P<0.001) and from 6.2±1.6 to 5.6±0.9 (P<0.001), respectively. Aspartate transaminase to platelet ratio index, FIB-4 index, and fibrosis index changed from 3.6±4.5 to 1.5±1.5 (P<0.001), from 7.0±6.2 to 3.9±2.8 (P<0.001), and from 3.3±0.9 to 2.5±1.1 (P<0.001), respectively. Conclusions: After 2 years of treatment, ETV improves liver function and non-invasive fibrosis markers in patients with HBV-associated cirrhosis.

Original languageEnglish
Pages (from-to)1775-1781
Number of pages7
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume30
Issue number12
DOIs
Publication statusPublished - 2015 Dec 1

Fingerprint

Hepatitis B virus
Fibrosis
Liver
End Stage Liver Disease
Therapeutics
Aspartate Aminotransferases
Blood Platelets
entecavir
Chronic Hepatitis B

Keywords

  • Entecavir
  • Hepatitis B virus
  • Liver fibrosis
  • Liver function

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Improvement of liver function and non-invasive fibrosis markers in hepatitis B virus-associated cirrhosis : 2years of entecavir treatment. / Shin, Seung Kak; Kim, Jeong Han; Park, Hyeonsu; Kwon, Oh Sang; Lee, Hyun Jung; Yeon, Jong Eun; Byun, Kwan Soo; Suh, Sang Jun; Yim, Hyung Joon; Kim, Yun Soo; Kim, Ju Hyun.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 30, No. 12, 01.12.2015, p. 1775-1781.

Research output: Contribution to journalArticle

Shin, Seung Kak ; Kim, Jeong Han ; Park, Hyeonsu ; Kwon, Oh Sang ; Lee, Hyun Jung ; Yeon, Jong Eun ; Byun, Kwan Soo ; Suh, Sang Jun ; Yim, Hyung Joon ; Kim, Yun Soo ; Kim, Ju Hyun. / Improvement of liver function and non-invasive fibrosis markers in hepatitis B virus-associated cirrhosis : 2years of entecavir treatment. In: Journal of Gastroenterology and Hepatology (Australia). 2015 ; Vol. 30, No. 12. pp. 1775-1781.
@article{9223a5a9891444de866b84df1a5c6b8a,
title = "Improvement of liver function and non-invasive fibrosis markers in hepatitis B virus-associated cirrhosis: 2years of entecavir treatment",
abstract = "Background and Aim: Entecavir (ETV) induces biochemical and histologic improvement of the liver in patients with chronic hepatitis B. This study aimed to confirm that 2years of ETV treatment improves liver function and non-invasive fibrosis markers in patients with hepatitis B virus (HBV)-associated cirrhosis. Methods: A total 472 na{\"i}ve patients with HBV-associated cirrhosis was treated with ETV for at least 2years, between March 2007 and December 2012. Model for end-stage liver disease and Child-Pugh (CP) score were used to evaluate the improvement of liver function. Aspartate transaminase to platelet ratio index, FIB-4 index, and fibrosis index were used to evaluate the improvement of fibrosis. Results: The final 370 of 472 patients with HBV-associated cirrhosis were enrolled. Mean age was 51±10years, and 240 patients (64.9{\%}) were men. The distribution of CP class was 71.1{\%} in A, 24.6{\%} in B, and 4.3{\%} in C. Mean end-stage liver disease and CP score changed over the study period from 8.5±4.6 to 6.2±4.2 (P<0.001) and from 6.2±1.6 to 5.6±0.9 (P<0.001), respectively. Aspartate transaminase to platelet ratio index, FIB-4 index, and fibrosis index changed from 3.6±4.5 to 1.5±1.5 (P<0.001), from 7.0±6.2 to 3.9±2.8 (P<0.001), and from 3.3±0.9 to 2.5±1.1 (P<0.001), respectively. Conclusions: After 2 years of treatment, ETV improves liver function and non-invasive fibrosis markers in patients with HBV-associated cirrhosis.",
keywords = "Entecavir, Hepatitis B virus, Liver fibrosis, Liver function",
author = "Shin, {Seung Kak} and Kim, {Jeong Han} and Hyeonsu Park and Kwon, {Oh Sang} and Lee, {Hyun Jung} and Yeon, {Jong Eun} and Byun, {Kwan Soo} and Suh, {Sang Jun} and Yim, {Hyung Joon} and Kim, {Yun Soo} and Kim, {Ju Hyun}",
year = "2015",
month = "12",
day = "1",
doi = "10.1111/jgh.13020",
language = "English",
volume = "30",
pages = "1775--1781",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Improvement of liver function and non-invasive fibrosis markers in hepatitis B virus-associated cirrhosis

T2 - 2years of entecavir treatment

AU - Shin, Seung Kak

AU - Kim, Jeong Han

AU - Park, Hyeonsu

AU - Kwon, Oh Sang

AU - Lee, Hyun Jung

AU - Yeon, Jong Eun

AU - Byun, Kwan Soo

AU - Suh, Sang Jun

AU - Yim, Hyung Joon

AU - Kim, Yun Soo

AU - Kim, Ju Hyun

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background and Aim: Entecavir (ETV) induces biochemical and histologic improvement of the liver in patients with chronic hepatitis B. This study aimed to confirm that 2years of ETV treatment improves liver function and non-invasive fibrosis markers in patients with hepatitis B virus (HBV)-associated cirrhosis. Methods: A total 472 naïve patients with HBV-associated cirrhosis was treated with ETV for at least 2years, between March 2007 and December 2012. Model for end-stage liver disease and Child-Pugh (CP) score were used to evaluate the improvement of liver function. Aspartate transaminase to platelet ratio index, FIB-4 index, and fibrosis index were used to evaluate the improvement of fibrosis. Results: The final 370 of 472 patients with HBV-associated cirrhosis were enrolled. Mean age was 51±10years, and 240 patients (64.9%) were men. The distribution of CP class was 71.1% in A, 24.6% in B, and 4.3% in C. Mean end-stage liver disease and CP score changed over the study period from 8.5±4.6 to 6.2±4.2 (P<0.001) and from 6.2±1.6 to 5.6±0.9 (P<0.001), respectively. Aspartate transaminase to platelet ratio index, FIB-4 index, and fibrosis index changed from 3.6±4.5 to 1.5±1.5 (P<0.001), from 7.0±6.2 to 3.9±2.8 (P<0.001), and from 3.3±0.9 to 2.5±1.1 (P<0.001), respectively. Conclusions: After 2 years of treatment, ETV improves liver function and non-invasive fibrosis markers in patients with HBV-associated cirrhosis.

AB - Background and Aim: Entecavir (ETV) induces biochemical and histologic improvement of the liver in patients with chronic hepatitis B. This study aimed to confirm that 2years of ETV treatment improves liver function and non-invasive fibrosis markers in patients with hepatitis B virus (HBV)-associated cirrhosis. Methods: A total 472 naïve patients with HBV-associated cirrhosis was treated with ETV for at least 2years, between March 2007 and December 2012. Model for end-stage liver disease and Child-Pugh (CP) score were used to evaluate the improvement of liver function. Aspartate transaminase to platelet ratio index, FIB-4 index, and fibrosis index were used to evaluate the improvement of fibrosis. Results: The final 370 of 472 patients with HBV-associated cirrhosis were enrolled. Mean age was 51±10years, and 240 patients (64.9%) were men. The distribution of CP class was 71.1% in A, 24.6% in B, and 4.3% in C. Mean end-stage liver disease and CP score changed over the study period from 8.5±4.6 to 6.2±4.2 (P<0.001) and from 6.2±1.6 to 5.6±0.9 (P<0.001), respectively. Aspartate transaminase to platelet ratio index, FIB-4 index, and fibrosis index changed from 3.6±4.5 to 1.5±1.5 (P<0.001), from 7.0±6.2 to 3.9±2.8 (P<0.001), and from 3.3±0.9 to 2.5±1.1 (P<0.001), respectively. Conclusions: After 2 years of treatment, ETV improves liver function and non-invasive fibrosis markers in patients with HBV-associated cirrhosis.

KW - Entecavir

KW - Hepatitis B virus

KW - Liver fibrosis

KW - Liver function

UR - http://www.scopus.com/inward/record.url?scp=84954442333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954442333&partnerID=8YFLogxK

U2 - 10.1111/jgh.13020

DO - 10.1111/jgh.13020

M3 - Article

C2 - 26095700

AN - SCOPUS:84954442333

VL - 30

SP - 1775

EP - 1781

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 12

ER -